CEO Spyridon Papapetropoulos transitions to interim CEO under consulting agreement

Neuphoria Therapeutics Inc.

Employment terminated Dec 31, 2025; Papapetropoulos remains on Board of Directors.
Consulting agreement effective Jan 1, 2026; $800/hr for up to ~40 hours/month.
Agreement terminates upon consummation of strategic transaction or after 12 months.
Severance includes annual base salary, target bonus, and medical premiums under prior employment agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.